Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals

Clinical Pharmacokinetics

Volumn 44, Issue 8, 2005, Pages 849-861

  Kappelhoff, Bregt S ^a   Huitema, Alwin D R ^a   Yalvaç, Zeynep ^b   Prins, Jan M ^b   Mulder, Jan W ^a   Meenhorst, Pieter L ^a   Beijnen, Jos H ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BILIRUBIN; CETIRIZINE; COTRIMOXAZOLE; EFAVIRENZ; FLUCONAZOLE; METHADONE; PREDNISONE; RIFAMPICIN; TEMAZEPAM;

ADULT; ARTICLE; ASIAN; BAYES THEOREM; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CLINICAL CHEMISTRY; COHORT ANALYSIS; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DATA BASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; PRIORITY JOURNAL; QUANTITATIVE ASSAY; STATISTICAL MODEL; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

ABSORPTION; ADULT; ANTI-HIV AGENTS; COMPUTER SIMULATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OXAZINES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 20044388655     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544080-00006     Document Type: Article

References (32)

1. Adkins JC, Noble S. Efavirenz. Drugs 1998 Dec; 56 (6): 1055-64
2. Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999 Sep; 180 (3): 862-4
3. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40 (12): 893-905
4. Joshi AS, Barret JS, Fiske WD, et al. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy [abstract no. 1201]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco
5. Nunez M, Gonzalez DR, Gallego L, et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001 Dec; 28 (4): 399-400
6. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001 Jan; 15 (1): 71-5
7. Fiske WD, Benedek I, Brennan J, et al. Pharmacokinetics of efavirenz in subjects with chronic liver disease [abstract no. 367]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago
8. Peyriere H, Mauboussin JM, Rouanet I, et al. Management of sudden psychiatric disorders related to efavirenz. AIDS 2001 Jul; 15 (10): 1323-4
9. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41 (9): 681-90
10. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003 Jan; 47 (1): 130-7
11. Wegner A, Vahey M, Dolan M, et al. Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy [abstract no. 428-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Chicago
12. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003 Jan; 73 (1): 20-30
13. Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001 Jul; 184 (1): 37-42
14. Veldkamp AI, van Heeswijk RP, Meenhorst PL, et al. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1999 Oct; 734 (1): 55-61
15. Beal S, Sheiner L. NONMEM user's guides: NONMEM Project Group. San Francisco (CA): University of California, 1998
16. de Maat MM, Ekhart GC, Huitema AD, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42 (3): 223-82
17. Karlsson MO, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998 Apr; 26 (2): 207-46
18. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001 Apr; 28 (2): 171-92
19. Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999 Nov; 48 (5): 712-5
20. Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002 May; 71 (5): 334-48
21. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002 Nov; 54 (10): 1271-94
22. de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999 Dec; 37 (6): 485-505
23. Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998 Apr; 45 (4): 355-9
24. Kinirons MT, Lang CC, He HB, et al. Triazolam pharmacoki netics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol 1996 Jan; 41 (1): 69-72
25. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002 Mar; 12 (2): 121-32
26. Tateishi T, Watanabe M, Nakura H, et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 2001 May; 69 (5): 333-9
27. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994 Jul; 270 (1): 414-23
28. Sowunmi A, Rashid TJ, Akinyinka OO, et al. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol 1995 Nov; 40 (5): 489-93
29. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41 (11): 813-51
30. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000 Feb; 14 (3): 237-42
31. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42 (1): 59-98
32. Hooiveld GJ, van Montfoort JE, Meijer DK, et al. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur J Pharm Sci 2001 Feb; 12 (4): 525-43